Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,303.09 +56.41 (+1.08%) Dow
39,848.56 +290.45 (+0.73%) Nasdaq
16,734.93 +223.75 (+1.36%) Bitcoin USD
65,031.41 +3,817.20 (+6.24%) CMC Crypto 200
1,373.96 +106.02 (+8.36%)
LLY Jun 2024 370.000 put
- Benzinga
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatid
- Zacks
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
- Reuters
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country. The British market could provide a glimpse into how the fight for patients among private suppliers could develop as drugmakers Novo Nordisk and Eli Lilly ramp up production. Growing competition between retailers has raised fears that some patients who buy the drugs themselves, amid limited capacity of the National Health Service, will miss out on long-term aftercare if they keep switching providers.
